Patents by Inventor Donald C. Porter

Donald C. Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-AMINO-4-[4-[4 (DIMETHYLCARBAMOYL) PHENYL]-1,4-DIAZEPAN-1-YL]THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE FOR USE IN CANCER THERAPY AND FORMULATIONS COMPRISING THE SAME
    Publication number: 20220226343
    Abstract: Disclosed herein are methods of using 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2-carboxamide or deuterated analogues thereof for treating cancers and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: May 21, 2020
    Publication date: July 21, 2022
    Inventors: Igor RONINSON, Mengqian CHEN, Jing LI, Jiaxin LIANG, Donald C. PORTER, Campbell MCINNES
  • CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
    Patent number: 10993945
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 4, 2021
    Assignee: SENEX BIOTECHNOLOGY, INC.
    Inventors: Igor B Roninson, Donald C Porter
  • Cell-based methods for measuring activity of a protein inhibitor
    Patent number: 10584369
    Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Senex Biotechnology, Inc.
    Inventors: Igor B Roninson, Donald C Porter, Serena Altilia
  • TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
    Publication number: 20200048208
    Abstract: The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Applicant: Senex Biotechnology, Inc.
    Inventors: Donald C. PORTER, Igor B. RONINSON
  • CDK8-CDK19 SELECTIVE INHIBITORS AND THEIR USE IN ANT-METASTAIC AND CHEMOPREVENTATIVE METHODS FOR CANCER
    Publication number: 20170071942
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 16, 2017
    Applicant: SENEX BIOTECHNOLOGY INC
    Inventors: IGOR B. RONINSON, DONALD C PORTER
  • CDKI pathway inhibitors and uses thereof
    Patent number: 9409873
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: August 9, 2016
    Assignee: SENEX BIOTECHNOLOGY INC.
    Inventors: Donald C Porter, Igor B Roninson, Mark P Wentland
  • CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
    Patent number: 9321737
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: April 26, 2016
    Assignee: SENEX BIOTECHNOLOGY INC
    Inventors: Igor B Roninson, Donald C Porter, Mark P Wentland
  • CDKI PATHWAY INHIBITORS AND USES THEREOF
    Publication number: 20140378683
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 25, 2014
    Inventors: DONALD C. PORTER, Igor B. Roninson, Mark P. Wentland
  • CELL-BASED METHODS FOR MEASURING ACTIVITY OF A PROTEIN INHIBITOR
    Publication number: 20140199708
    Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.
    Type: Application
    Filed: January 13, 2014
    Publication date: July 17, 2014
    Applicant: SENEX BIOTECHNOLOGY INC.
    Inventors: Igor B. Roninson, Donald C. Porter, Serena Altilia
  • CDK8-CDK19 SELECTIVE INHIBITORS AND THEIR USE IN ANTI-METASTATIC AND CHEMOPREVENTATIVE METHODS FOR CANCER
    Publication number: 20140038958
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
    Type: Application
    Filed: February 1, 2013
    Publication date: February 6, 2014
    Applicant: SENEX BIOTECHNOLOGY INC.
    Inventors: Igor B. Ronnison, Donald C. Porter, Mark P. Wentland
  • CDKI pathway inhibitors and uses thereof
    Patent number: 8598344
    Abstract: The invention relates to compounds for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 3, 2013
    Assignee: Senex Biotechnology
    Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland
  • CDKI PATHWAY INHIBITORS AND USES THEREOF
    Publication number: 20120071477
    Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Application
    Filed: November 30, 2010
    Publication date: March 22, 2012
    Applicant: Senex Biotechnology, Inc.
    Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland